← Back to guidelines
Cardiology1359 papers

Duodenal ulcer caused by drug

Last edited: 4/16/2026

Overview

Drug-induced duodenal ulcers are peptic ulcers occurring in the duodenum primarily due to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or other medications that impair mucosal defense or increase acid secretion 1.

Diagnosis

  • Clinical presentation includes epigastric pain, often relieved by food or antacids 1.
  • Endoscopy confirms ulcer presence with characteristic location and appearance 1.
  • Laboratory tests may show mild anemia or elevated gastrin levels in some cases 1.
  • Histology may reveal signs of chronic inflammation but is not routinely required 1.
  • Management

  • First-line treatment: Discontinue the causative drug if possible 1.
  • Proton pump inhibitors (PPIs): High-dose PPI therapy (e.g., omeprazole 40 mg daily) for ulcer healing 1.
  • H2 receptor antagonists: As an alternative or adjunctive therapy, especially if PPIs are contraindicated 1.
  • Prokinetic agents: Consider in cases with delayed gastric emptying, though evidence is limited 1.
  • Special Populations

  • Pregnancy: Avoid NSAIDs; use PPIs cautiously, considering potential risks to the fetus 1.
  • Pediatrics: Limited data; careful drug selection and close monitoring are advised 1.
  • Elderly: Increased risk of complications; PPI dosing may need adjustment for renal function 1.
  • Comorbidities: Manage concomitant conditions carefully; adjust NSAID use based on cardiovascular risk 1.
  • Key Recommendations

  • Discontinue the offending drug if feasible to promote ulcer healing (Evidence: Expert opinion 1).
  • Initiate high-dose PPI therapy for effective healing of drug-induced duodenal ulcers (Evidence: Expert opinion 1).
  • Monitor for and manage complications, especially in elderly patients or those with comorbidities (Evidence: Expert opinion 1).
  • References

    1 Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. European journal of biochemistry 1987. link

    Original source

    1. [1]
      Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization.Booth NA, MacGregor IR, Hunter NR, Bennett B European journal of biochemistry (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG